NCT00424541View on ClinicalTrials.gov

Pharmacokinetic and Pharmacodynamic Profiles of Aliskiren in Japanese Patients With Mild to Moderate Essential Hypertension

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 31, 2007

Study Completion Date

August 31, 2007

Conditions
Hypertension
Interventions
DRUG

SPP100 (aliskiren)

Trial Locations (1)

160-8618

Novartis Investigative Site, Tokyo

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY